Association of Early Physician Follow-up With Readmission Among Patients Hospitalized for Acute Myocardial Infarction, Congestive Heart Failure, or Chronic Obstructive Pulmonary Disease.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 07 2022
Historique:
entrez: 12 7 2022
pubmed: 13 7 2022
medline: 15 7 2022
Statut: epublish

Résumé

A better understanding of the association between early physician follow-up after discharge and adverse outcomes among hospitalized patients may inform interventions aimed at reducing readmission for common chronic conditions. To assess whether hospitalized patients with early physician follow-up after discharge had lower rates of overall and condition-specific readmissions within 30 days and 90 days of discharge. This cohort study was conducted among Ontario, Canada, adults with first admission for acute myocardial infarction (AMI), congestive heart failure (CHF), or chronic obstructive pulmonary disease (COPD) during 2005 to 2019. The exposure was follow-up visit with a primary care physician or relevant specialist within 7 days of discharge. Cox proportional hazards models were used to compare patients with vs without early follow-up, adjusting for sociodemographic factors and comorbidities, weighting by propensity score-based overlap weights. Data were analyzed from January through July 2021. Primary outcomes were 30-day and 90-day readmissions, cardiac readmissions (readmission for AMI, CHF, or angina) for patients with cardiac conditions, and COPD-related readmissions for patients with COPD. Mortality at 30 days and 90 days was a secondary outcome. All percentages reported in Results are unweighted. The study cohort comprised 450 746 patients, including 198 854 patients with AMI, 133 058 patients with CHF, and 118 834 patients with COPD; the median (IQR) age was 66 (56-77) years for AMI, 78 (68-85) years for CHF, and 73 (64-81) years for COPD, and there were 64 339 (32.35%) women, 62 575 (47.03%) women, and 59 179 (49.80%) women, respectively. There were 91 182 patients (45.85%), 56 491 patients (42.46%), and 40 159 patients (33.79%), respectively, who received an early follow-up visit. Overall, patients with early follow-up had higher rates of collaborative care (eg, CHF: 20 931 patients [37.85%] vs 11 101 of 76 567 patients [14.85%]) and visits to a specialist within 30 days (eg, CHF: 25 797 patients [45.67%] vs 20 548 patients [26.84%]). Those with early follow-up had lower 90-day readmission rates among patients with CHF (15 934 patients [28.21%] vs 23 121 patients [30.20%]; adjusted hazard ratio [aHR], 0.98; 95% CI, 0.96-0.99) and among those with COPD (8784 patients [21.87%] vs 18 097 of 78 675 patients [23.00%]; aHR, 0.95; 95% CI, 0.93-0.98). Among patients with COPD, those with early follow-up had lower 90-day COPD-related readmission rates (4015 patients [10.00%] vs 8449 patients [10.74%]; aHR, 0.93; 95% CI, 0.89-0.96), and among patients with CHF, those with early follow-up had lower 90-day mortality rates (4044 patients [7.16%] vs 6281 patients [8.20%]; aHR, 0.93; 95% CI, 0.90-0.97). There were no significant benefits at 30 days or for patients with AMI. These findings suggest that early follow-up in conjunction with a comprehensive transitional care strategy for hospitalized patients with medically complex conditions coupled with ongoing effective chronic disease management may be associated with reduced 90-day readmissions.

Identifiants

pubmed: 35819782
pii: 2794153
doi: 10.1001/jamanetworkopen.2022.22056
pmc: PMC9277500
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2222056

Subventions

Organisme : CIHR
ID : FDN 143303
Pays : Canada

Références

Ann Intern Med. 2009 Feb 3;150(3):178-87
pubmed: 19189907
N Engl J Med. 2011 Dec 29;365(26):2445-7
pubmed: 22204720
Open Med. 2013 May 14;7(2):e40-55
pubmed: 24348884
JAMA. 2010 Oct 20;304(15):1715-6
pubmed: 20959584
Circ Heart Fail. 2021 Apr;14(4):e008335
pubmed: 33866827
N Engl J Med. 2013 Jan 10;368(2):100-2
pubmed: 23301730
JAMA. 2004 Mar 17;291(11):1358-67
pubmed: 15026403
JACC Heart Fail. 2017 Aug;5(8):578-588
pubmed: 28501521
Med Care. 2016 Apr;54(4):365-72
pubmed: 26978568
Am J Epidemiol. 2019 Jan 1;188(1):250-257
pubmed: 30189042
JAMA. 2020 Jun 16;323(23):2417-2418
pubmed: 32369102
Ont Health Technol Assess Ser. 2017 May 25;17(8):1-37
pubmed: 28638496
JAMA. 2010 May 5;303(17):1716-22
pubmed: 20442387
Lancet. 2016 Dec 3;388(10061):2721-2723
pubmed: 27924764
JAMA. 2013 Jan 23;309(4):355-63
pubmed: 23340637
Stat Methods Med Res. 2019 Oct-Nov;28(10-11):3142-3162
pubmed: 30203707
Arch Intern Med. 2010 Oct 11;170(18):1664-70
pubmed: 20937926
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
Ann Intern Med. 2010 Dec 7;153(11):757-8
pubmed: 21135299
BMC Cardiovasc Disord. 2016 Oct 11;16(1):195
pubmed: 27729027
Ann Intern Med. 2014 Jun 3;160(11):774-84
pubmed: 24862840
Eur J Heart Fail. 2017 Nov;19(11):1427-1443
pubmed: 28233442
Health Serv Res. 2021 Oct;56 Suppl 1:973-979
pubmed: 34378192
PLoS One. 2018 Apr 3;13(4):e0195222
pubmed: 29614131
N Engl J Med. 2002 Nov 21;347(21):1678-86
pubmed: 12444183
JAMA. 2019 Feb 26;321(8):753-761
pubmed: 30806695
Circulation. 2010 Nov 2;122(18):1806-14
pubmed: 20956211
CMAJ. 2018 Dec 17;190(50):E1468-E1477
pubmed: 30559279
Circulation. 2013 Sep 10;128(11):1206-13
pubmed: 23946265
Respir Care. 2019 Sep;64(9):1146-1156
pubmed: 31467155
JAMA. 2012 Mar 14;307(10):1037-45
pubmed: 22416099
Circulation. 2013 Sep 10;128(11):1177-8
pubmed: 23946266
Can J Cardiol. 2010 Apr;26(4):185-202
pubmed: 20386768
Am Heart J. 2021 Oct;240:1-10
pubmed: 33984316
N Engl J Med. 2009 Apr 2;360(14):1418-28
pubmed: 19339721
Ann Intern Med. 2011 Oct 18;155(8):520-8
pubmed: 22007045
Stat Med. 2013 Jul 20;32(16):2837-49
pubmed: 23239115
J Am Coll Cardiol. 2001 Mar 15;37(4):992-7
pubmed: 11263626

Auteurs

Farah E Saxena (FE)

Canadian Partnership Against Cancer, Toronto, Canada.

Arlene S Bierman (AS)

Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Rockville, Maryland.

Richard H Glazier (RH)

ICES, Toronto, Ontario, Canada.
Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Department of Family and Community Medicine, St Michael's Hospital, Toronto, Ontario, Canada.

Xuesong Wang (X)

ICES, Toronto, Ontario, Canada.

Jun Guan (J)

ICES, Toronto, Ontario, Canada.

Douglas S Lee (DS)

ICES, Toronto, Ontario, Canada.
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre, Toronto, Ontario, Canada.

Therese A Stukel (TA)

ICES, Toronto, Ontario, Canada.
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH